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The advent of hybridoma technology has rekindled hopes of using antibodies 
as specific therapeutic  agents (1-4).  Several reports have focused attention  on 
the potential  use of monoclonal  antibodies (mAb) 1 either as antitumor  agents 
(4-15) or as immunosuppressive agents designed to facilitate organ transplanta- 
tion (16-21). Early therapeutic trials in humans have demonstrated that certain 
mAb can be used to retard the progression of lymphoid malignancy (10,  1 1) or 
to reverse renal allograft rejection (17, 18). However, in most cases, the beneficial 
effects of treatment have been transient  (4,  12-17) due in part to the develop- 
ment of host immunity to the administered mAb (4, 9,  16,  17). 
Recently, (22) we treated three murine  models for systemic lupus erythema- 
tosus (SLE) with  biweekly injections of rat  anti-T  cell (anti-Thy-l.2)  mAb in 
order to examine the role of T  cells in the pathogenesis of murine lupus and to 
explore  the  possibility of using  antilymphocyte  mAb  to  treat  autoimmunity. 
Treatment with anti-Thy-1.2 substantially reduced circulating T  cells in all three 
strains (MRL/lpr,  NZB/NZW FI, BXSB), despite development of antibodies to 
rat  Ig.  Therapy  was  beneficial  in  MRL/lpr  mice.  It  reduced  autoantibody 
production,  retarded  renal  disease, and  markedly prolonged  life.  In  contrast, 
treatment  did not reduce autoimmunity  in  NZB/NZW Fl  (B/W) mice, and  it 
caused fatal anaphylaxis in BXSB mice. These findings demonstrate that antilym- 
phocyte mAb can serve as specific probes to examine the cells that contribute to 
autoimmunity.  The results in MRL/lpr mice illustrate the potential therapeutic 
value of antilymphocyte mAb when a  pathogenic  cell subset can be identified. 
However, the results in BXSB mice emphasize equally the potential hazards of 
the host immune response to treatment with mAb. 
The  development of a  new rat  mAb (GK1.5) reactive with  mouse helper T 
cells provides an opportunity for a more selective approach to the study of T  cell 
regulation of autoimmunity in murine lupus. This antibody recognizes a  glyco- 
protein antigen, designated L3T4, that is the mouse homologue for the human 
T  cell  antigen  termed  Leu-3  or  T4  (23).  Like  Leu-3/T4  in  humans,  L3T4 
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participates in the T  cell response to class II major histocompatibility antigens 
(MHA II) on antigen-presenting  cells (24-28).  Antibody to L3T4 inhibits most 
MHA II-dependent T  cell responses in vitro (25-27). Therefore, administration 
of  mAb  against  L3T4  might  alter  immune  responses  in  vivo  and  thereby 
influence the course of autoimmune disease. To test this hypothesis, we treated 
B/W female mice with weekly injections of GK1.5 (anti-L3T4) beginning at age 
4 mo. Treatment produced a sustained reduction in circulating T  cells expressing 
L3T4. It also dramatically reduced autoantibody concentrations, retarded renal 
disease,  and  prolonged  life.  Mice treated  with  rat  anti-L3T4  mAb developed 
little or no antibody to the administered rat Ig. In contrast, control mice treated 
with purified nonimmune  rat  IgG developed high  titers of antibody to rat  Ig. 
These  findings  establish  that  autoimmune  disease  in  B/W  mice  is  T  cell- 
dependent.  They further demonstrate  that:  (a) mAb directed against helper T 
cells can  significantly  improve autoimmune  disease in  B/W  mice;  and  (b) the 
beneficial effects of treatment  with anti-L3T4  may not be complicated by the 
development of a host immune response to therapy. 
Materials and Methods 
Mice.  B/W mice were bred in our colony at the San Francisco Veterans Administration 
Medical Center from NZB females, purchased from The Jackson Laboratory, Bar Harbor, 
ME, and NZW males purchased from Simonsen Laboratory, Gilroy, CA 
Treatment  Regimen.  10  mice  were  treated  with  a  rat  IgG2b  mAb  against  L3T4, 
designated GK1.5 (23). The hybridoma used to produce GK1.5 was generously provided 
by Dr. Frank W. Fitch, University of Chicago. Antibody to L3T4 was harvested as ascites 
from sublethally irradiated BALB/c mice, partially purified by ammonium sulfate precip- 
itation,  dialyzed against phosphate-buffered saline, and quantified by protein electropho- 
resis and measurement of optical  density.  Treatment consisted  of an initial intravenous 
injection of 2 mg of anti-L3T4, followed by weekly intraperitoneal injections (2 mg per 
mouse).  In preliminary studies, we determined that an intravenous injection  of 2 mg of 
anti-L3T4 produces saturation binding of circulating and splenic target cells, and substan- 
tial, though incomplete, binding of L3T4  ÷ lymph node cells and thymocytes (unpublished 
data). Two control groups were also studied:  one group (10 mice) received weekly 2-mg 
injections  of chromatographically purified rat  IgG (Cappel  Laboratories, Cochranville, 
PA); the other group (11 mice) received saline. 
Fluorescence Analysis of  Lymphocyte Subpopulations.  Peripheral blood was obtained from 
individual mice by retroorbital bleeding into heparinized pipettes. Mononuclear cells were 
separated by centrifugation over Lympholyte-M  (Cedarlane  Laboratories, Ontario, Can- 
ada), and quantified using a Coulter ZBI cell counter (Coulter Electronics,  Inc., Hialeah, 
FL).  Mononuclear cell subsets were identified by staining  with  fluorescein-conjugated 
mAb, as described previously (29). The antibodies used for analysis included:  anti-Thy- 
1.2 (30-H12) to identify all T  cells, anti-L3T4 (GKI.5) and anti-Lyt-2  (53-6) to identify 
the major T  cell subsets, and anti-ThB (53-9) to identify B cells. Fluorescein-conjugated 
mouse anti-rat kappa chain  mAb (MAR 18.5; B-D FACS Systems, Sunnyvale,  CA) was 
used to detect anti-L3T4 on target cell surfaces.  Except as noted, fluorescence analysis 
was always performed immediately before treatment, i.e., 1 wk after the previous injection. 
Assessment of Renal Disease.  Blood urea nitrogen (BUN) was determined on samples 
from individual  mice using a CentrifiChem System 400 (Union Carbide, Danbury, CT). 
Proteinuria was measured colorimetrically  by the use of Albustix (Miles Laboratories Inc., 
Elkhart,  IN). This produces an approximation of proteinuria as follows: trace, 10 mg]dl; 
1+, 30 mg/dl;  2+,  100 mg/dl;  3+, 300 mg/dl; 4+,  1,000 mg/dl. All measurements of 
proteinuria were performed by an observer who had no knowledge of the given treatment. 
Measurement of Serum Antibodies to Double-stranded DNA.  Anti-DNA antibody concen- 
trations  were assessed by a  solid  phase  enzyme-linked  immunosorbent  assay (ELISA) 380  SUCCESSFUL  TREATMENT OF  NZB/NZW F1  MICE WITH  ANTI-L3T4 
derived from the method of Fish and Ziff (30). Immulon II polyvinyl microtitration trays 
were coated sequentially with a 50 #g/ml solution of poly-L-iysine (Sigma Chemical Co., 
St. Louis, MO) in 0.1  M  Tris-HC! buffer, pH 7.3 (75 #g/well), a  20 #g/ml solution of 
poly(dA-dT) (Sigma Chemical Co.) in Tris buffer (75 #l/well), and a 2% solution of bovine 
serum albumin (BSA) (Sigma Chemical Co.) in Tris buffer (250 #i/well). Serum samples 
that had been serially diluted in Tris buffer containing 1% BSA and 2% bovine gamma 
globulin (BGG) (Sigma Chemical Co.) were then incubated at 75 #l/well for 1.5 h at room 
temperature.  The wells  were then washed five times and  incubated with peroxidase- 
conjugated goat anti-mouse Ig that had been extensively absorbed with rat Ig (0.3 #g/ 
well; Cappel Laboratories). After incubation at room temperature for 1 h, the wells were 
washed five times and treated in the dark for 10 min with 0-phenylenediamine (100 #1/ 
well). The enzymatic reaction was stopped with 2 N H~SO4 (200 #l/well), and absorbance 
was  measured at  490  nm.  Serum from adult  MRL/lpr and C57BL/6 mice served as 
positive and negative controls, respectively. The specificity of the assay was demonstrated 
using wells that had not been coated with poly(dA-dT). 
Measurement of Serum Antibodies to Rat Ig.  Antibodies to rat Ig were measured by an 
ELISA  technique similar  to  the  one described above.  Briefly, Immulon  II  polyvinyl 
microtitration trays were coated with rat Ig mAb (0.5 #g 30-H12/well) followed by 2% 
BSA  in  0.1  M  Tris-HC1  buffer.  Serum  samples  were  serially diluted  in  Tris  buffer 
containing  1%  BSA  and  2%  BGG,  then  incubated  at  75  #l/well  for  1.5  h  at  room 
temperature. The wells  were then washed,  incubated with peroxidase-conjugated goat 
anti-mouse Ig that had been absorbed with rat Ig, washed again, and then treated in the 
dark with o-phenylenediamine exactly as described above. Mouse anti-rat kappa chain 
mAb (MAR  18.5) and normal  mouse serum served as positive and negative controls, 
respectively. 
Measurement of Serum IgM and IgG Levels.  Serum concentrations of mouse IgM and 
IgG were measured by ELISA.  lmmulon II polyvinyl microtitration trays were coated 
with a  10 #g/ml solution of either goat anti-mouse IgG or goat anti-mouse IgM (both, 
Cappel Laboratories), followed by 2%  BSA  in  0.1  M  Tris-HCI buffer. Serum samples 
were serially diluted in Tris buffer containing 1% BSA and 2% BGG, then incubated at 
75 #l/well for 1.5 h at room temperature. The wells were then washed, incubated with 
peroxidase-conjugated goat anti-mouse Ig that had been absorbed with rat Ig, washed 
again, and then treated in the dark with 0-phenylenediamine, as described above. Purified 
mouse IgM  and  IgG (Miles  Laboratories) were used to generate standard curves and 
document the specificity of the assay. 
Results 
Effect of  Age on Circulating Lymphocyte Subpopulations in Untreated B/W Mice.  In 
control B/W mice treated with saline,  there was a  spontaneous age-dependent 
reduction  in  circulating  T  lymphocytes  (Fig.  1,  A  and  B).  The  number  of 
circulating B  lymphocytes remained  relatively constant (Fig.  1 C).  Although  T 
cell counts fell by ~50%  between 4  and  8  mo of age,  L3T4  + cells and  Lyt-2  ÷ 
cells were comparably affected and, therefore, the L3T4/Lyt-2 (helper/suppres- 
sor)  ratio  remained  constant  (Fig.  1 D).  Treatment  with  weekly  injections  of 
nonimmune  rat  IgG  did  not  affect  the  spontaneous  progressive  changes  in 
circulating lymphocyte subpopulations in B/W mice. 
Effect of Treatment  With Anti-L3T4  mAb  on  Circulating Lymphocyte  Subpopula- 
tions.  Treatment of B/W mice with weekly injections of anti-L3T4 mAb pro- 
duced  a  dramatic  and  sustained  reduction  in  circulating  L3T4  +  lymphocytes 
(Fig.  1A).  Circulating  L3T4  ÷  cells were reduced by  30%  24  h  after the  first 
injection, by 90%  1 wk  later, and by 95%  thereafter.  Fluorescence analysis of 
circulating lymphocytes using mouse anti-rat  kappa  chain  mAb  demonstrated 
persistence of administered antibody on the few remaining target cells 7 d after WOFSY  AND  SEAMAN  381 
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FIGURE  1.  Circulating lymphocyte subpopulations  in B/W mice treated  with weekly injec- 
tions of saline (O), nonimmune rat IgG (&), or anti-L3T4  mAb (I) beginning at age 4 mo. 
Helper T  cells,  suppressor/cytotoxic T  cells,  and B cells  were identified  using fluorescein- 
conjugated anti-L3T4 mAb (A), anti-Lyt-2 (B), and anti-Thy B (C), respectively. The relative 
proportion of L3T4  + and Lyt-2  ÷ T cells is shown in D. 
injection. Staining with fluorescein-conjugated anti-Thy-1.2 mAb and anti-Lyt-2 
established that, after 1 wk of therapy, >90%  of circulating T  cells in treated 
mice expressed Lyt-2, indicating that the reduction in L3T4 + T  cells reflected 
target cell depletion rather than antigen modulation. The effect of treatment 
with anti-L3T4  was specific. The number of circulating B cells and Lyt-2  + T 
cells remained stable in treated mice (Fig.  1, B and C). The mean L3T4/Lyt-2 
ratio in treated mice was 0.1:1, compared with 2.6:1", in untreated mice. 
Host Immune Response to  Treatment.  Control mice treated with nonimmune 
rat IgG all developed high titers of antibody to rat Ig (Fig. 2).  Host antibodies 
were detectable 7 d after the first injection of rat IgG arm rapidly rose to a peak 
mean titer of 1:4,500.  In contrast, only 3 of 10 mice treated with rat anti-L3T4 
mAb developed antibodies to rat  Ig.  In these mice, antibodies to rat  Ig first 
appeared after 2-3 mo of therapy and were present only in relatively low titer 
(<1:400).  7 of the  10 treated mice never developed detectable antibody to rat 
Ig. This is in striking contrast to our previous observation that B/W mice treated 
with rat anti-Thy-l.2 mAb of the same isotype as anti-L3T4 all develop high 
titers of anti-rat Ig (22). 
Anti-L3T4  Reduces Autoimmunity.  Treatment of B/W  mice with anti-L3T4 
mAb prevented development of high titers of antibody to double-stranded DNA 
(Fig. 3). Although small amounts ofanti-DNA antibody appeared within the first 382  SUCCESSFUL  TREATMENT  OF  NZB/NZW  F|  MICE  WITH  ANTI-L3T4 
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FIGURE 2.  Geometric mean titer (-~- SEM)of antibodies to rat Ig in B/W mice treated with 
saline (O), nonimmune rat IgG (A), or anti-L3T4  mAb (E). The shaded area indicates assay 
results using normal mouse sera as negative controls. 
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FIGURE 3.  Geometric  mean  titer  (~  SEM) of  antibody  to  double-stranded  DNA  in 
B/W mice treated with saline (O), nonimmune rat IgG (A), or anti-L3T4 mAb (1). The shaded 
area indicates the titer of anti-DNA antibody (<1:200) in normal (C57BL/6) mice. 
2 mo of therapy with anti-L3T4, the titers of anti-DNA antibody were markedly 
lower in treated mice than in control mice, and the titers remained low through- 
out the duration of therapy. At age 8 mo, the geometric mean titer of anti-DNA 
antibody was  1:2,200  ~  1.2  in  mice treated with saline,  1:1,500  ~  1.5  in mice 
treated with nonimmune rat Ig, and  1:270 ;$1.1  in mice treated with anti-L3T4 
(P <  0.0005 compared with either control group; Student's t test). The reduction 
in anti-DNA antibody did not reflect a generalized reduction in total Ig levels in 
treated mice (Table I). After 4  mo of treatment, there was a  slight reduction in 
the mean IgG concentration  in treated mice that was not statistically significant. WOFSY AND SEAMAN  383 
TABLE  I 
Effect of Treatment on lg Concentration 
Treatment 
lgM*  IgG* 
4-mo-old  8-mo-old  4-mo-old  8-mo-old 
Saline  9.5 3= 0.2  9.2 3= 0.2  15.5 3= 0.2  15.7 3= 0.2 
Rat IgG  9.6 3= 0.2  9.6 3= 0.2  15.7 3= 0.3  15.5 3= 0.6 
Anti-L3T4  9.6 3= 0.2  10.3 3= 0.2*  15.5 3= 0.3  15.2 3= 0.3 
* Log~ titer (~ 3= SEM) as measured by ELISA. 
* P < 0.05 compared to pretreatment IgM levels and to IgM levels in both control groups. 
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FIGUnE 4.  Mean BUN in B/W mice treated with saline (O), nonimmune rat lgG (&) or anti- 
L3T4 mAb (I). 
However, there  was  a  significant  increase  in  the  mean  IgM  concentration  in 
treated mice compared with pretreatment levels, and with IgM levels in control 
mice. Increased plasma IgM has been reported previously (31) in association with 
successful treatment of B/W mice. 
Anti-L3T4 Reduces Renal Disease.  The reduction in anti-DNA antibody con- 
centration  in  mice  treated  with  anti-L3T4  was  associated  with  a  significant 
reduction  in  renal  disease.  Renal  function,  as  assessed  by BUN,  deteriorated 
steadily  in  both  control  groups,  but  was  preserved in  mice treated  with  anti- 
LST4 (Fig.  4).  Renal  insufficiency occurred earliest in mice treated with  non- 
immune rat IgG, perhaps as a  consequence of the host immune response to rat 
Ig. At age 7  mo, the mean BUN in mice treated with rat IgG was 34.2 _+  12.1 
mg/dl,  compared to  18.5  _+  2.7  mg/dl  in  mice treated  with  saline  (P <  0.05; 
Mann-Whitney  U  test) and  13.1  _+  0.8  mg/dl  in  mice treated  with  anti-L3T4 
(P <  0.01  compared with  rat  IgG  treatment;  P  <  0.05  compared with  saline 
treatment). By 9  mo, the mean BUN in mice treated with saline rose to 38.0 + 
11.6 mg/dl, compared with  14.3 _+ 0.9 mg/dl in mice treated with anti-L3T4 (P 384  SUCCESSFUL  TREATMENT OF  NZB/NZW  F|  MICE  WITH ANTI-L3T4 
<  0.01). Severe proteinuria (--_3+) developed in 50-60% of mice in each control 
group,  but  in  none  of the  mice treated  with  anti-L3T4  (P <  0.05;  chi-square 
analysis) (Fig. 5). Moderate proteinuria (2+) developed in  16 of 21  control mice 
but  in  only 2  of 10  treated  mice (P <  0.05).  These  two mice were among the 
three  treated  mice that  developed  low titers  of antibody  to  rat  Ig,  suggesting 
that the immune response to rat Ig may have contributed to the development of 
proteinuria. 
Anti-L3T4 Prolongs Survival.  Treatment  with  anti-L3T4  mAb dramatically 
prolonged life (Fig.  6).  Median  survival was 9.3  mo in mice treated with saline 
and 7.6 mo in mice treated with rat IgG. In contrast, all of the mice treated with 
anti-L3T4  are  still  alive at  10  mo.  The  difference  in  10-mo survival between 
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FIGURE 5.  Frequency of significant proteinuria  in B/W mice treated with saline (O), nonim- 
mune rat IgG (&), or anti-L3T4 mAb (11). (.4) Percent  of mice with proteinuria  >2+ (100 
mg/dl).  (B) Percent  of mice with proteinuria  >3+ (300 mg/dl).  To reflect accurately  the 
development of renal disease in all mice, each point reflects the current level of proteinuria in 
surviving mice, as well as the last measurement of proteinuria  in deceased mice. 
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FIGURE 6.  Survival  in B/W mice treated with saline (O), nonimmune  rat IgG (l), or anti- 
L3T4 mAb (11). WOFSY  AND  SEAMAN  385 
mice treated with anti-L3T4 and control mice is strongly significant (P <  0.001 
compared with the saline control group; P <  0.00001 compared with the rat IgG 
control group; chi-square analysis). The difference in mean survival between the 
two control groups is also statistically significant (P <  0.05; t test), i.e., treatment 
with nonimmune rat Ig accelerated mortality. 
Discussion 
To clarify the role of helper T  cells in the pathogenesis of autoimmune disease 
in the B/W model for SLE, we treated female B/W mice with repeated injections 
of a rat mAb directed against the mouse helper T  cell antigen, L3T4. Treatment 
depleted  circulating  target  cells,  reduced  autoantibody  production,  retarded 
renal disease, and prolonged life. Moreover, treated mice produced little or no 
host antibodies to the administered rat mAb. These findings provide the first 
clear demonstration that autoimmune disease in B/W mice is T  cell dependent. 
They further suggest that mAb directed against specific helper T  cell antigens 
may be effective in the treatment of certain autoimmune diseases, and that the 
therapeutic  benefit  may be  achieved  without provoking an  undesirable,  and 
potentially hazardous, immune response to the mAb. 
For two decades, the B/W strain has been studied (32, 33) as a model for SLE 
in humans. Early studies (34-37)  focused attention on T  cell abnormalities in 
B/W mice, emphasizing defects in suppressor T cell number and function. Recent 
studies, however, have cast doubt on the significance of these T cell abnormalities. 
For example, neonatal thymectomy has little effect on the course of autoimmu- 
nity in B/W  mice (38),  but elimination of a  specific subset of B  cells prevents 
autoimmune disease (39). Other studies, demonstrating B cell abnormalities, and 
indicating that 13 cell abnormalities may precede demonstrable T  cell abnormal- 
ities in B/W mice, have suggested that autoimmunity in these mice may reflect a 
primary B cell defect, and that T  cell defects may be secondary phenomena (40- 
43). Our results demonstrate conclusively that T  cells, specifically helper T  cells, 
play an important role in the pathogenesis of autoimmune disease in B/W mice. 
If primary defects occur in other cell types, particularly  B  lymphocytes, these 
cells nonetheless require helper T  cells for the expression of disease. 
It has been postulated that autoimmunity in B/W mice might reflect selective 
loss of suppressor T  cells (36,  37), perhaps as a  consequence of the action of 
natural thymocytotoxic antibodies (44, 45). Our findings in untreated B/W mice 
show that, although progressive T  lymphocytopenia occurs, there is no selective 
effect  on  suppressor  (Lyt-2  +)  T  cells.  Rather,  both  major  T  cell  subsets  are 
comparably reduced, and the L3T4/Lyt-2 ratio is unchanged. There is, thus, no 
numerical imbalance between helper and suppressor/cytotoxic T  cells, although 
functional differences cannot be excluded. 
The  L3T4  molecule  is  expressed  on  a  distinct  subpopulation  of  T  cells 
previously  referred  to  descriptively as  helper  T  cells.  More  precisely,  L3T4 
identifies T  cells that respond to MHA II on antigen-presenting cells (24-27). 
The functional importance of the L3T4 molecule is demonstrated by the obser- 
vation that mAb against L3T4 blocks in vitro T  cell responses to MHA II (25- 
27). The beneficial effects ofanti-L3T4 in B/W mice may, therefore, be due not 
only to target cell depletion, but also to direct inhibition of T  cell responses that 386  SUCCESSFUL  TREATMENT OF  NZB/NZW Fl  MICE WITH ANTI-L3T4 
are dependent on the recognition of MHA II. The latter mechanism would imply 
that autoimmunity, like immunity to foreign antigens, requires a T  cell response 
to  MHA  II.  Our results are compatible with this possibility,  but  they do not 
prove it.  We previously (22) treated B/W  mice with mAb against Thy-l.2, an 
antigen expressed on all T  cells. Although treatment reduced circulating L3T4 ÷ 
T  cells by 75%,  there was a  comparable reduction in  Lyt-2  + T  cells, and no 
improvement in autoimmunity. The failure of anti-Thy-1.2 to improve autoim- 
munity despite depletion of L3T4 + cells suggests either that:  (a) regulation of 
autoimmunity in B/W mice involves a balance between L3T4  ÷ cells and Lyt-2  ÷ 
cells  that  is  not  disturbed  by  treatment  with  anti-Thy-l.2;  or  (b)  successful 
treatment with anti-L3T4 requires functional impairment of the L3T4 molecule. 
An important observation in our present studies was the relative lack of host 
immunity to the anti-L3T4 antibody. Previous attempts to use mAb as therapeu- 
tic agents in humans and in mice have been complicated by the development of 
a host immune response to the mAb (4, 9, 16,  17, 22). In B/W mice treated with 
rat anti-Thy-l.2 mAb (subclass IgG2b), the development of antibody to rat Ig 
was associated with accelerated mortality, even though autoimmunity was not 
affected (22).  In autoimmune BXSB mice, treatment with anti-Thy-l.2 caused 
fatal anaphylaxis (22). The current study reemphasizes the potential hazards of 
treatment with foreign Ig, because administration of purified nonimmune rat 
IgG  significantly  reduced  survival.  In  this  context,  the  weak  host  immune 
response to rat anti-L3T4  mAb (subclass IgG2b)  takes on added significance. 
The  ability  to  administer  anti-L3T4  without  generating  high  titers  of host 
antibody to rat Ig may not only maximize the therapeutic effect of anti-L3T4, it 
may also minimize the risks associated with the host immune response to foreign 
protein. 
The  lack of host immunity to  repeated injections of anti-L3T4  is  the first 
demonstration that anti-L3T4  can interrupt the immune response in  vivo.  It 
remains to be determined if anti-L3T4 will block the in vivo response to foreign 
antigens other than itself, although it has been demonstrated (25) that anti-L3T4 
can block in vitro responses to foreign antigens that are presented in association 
with MHA II. Immune recognition of MHA II can also be blocked both in vitro 
and in vivo by mAb against MHA II (46-49). One group of researchers (50-52) 
have treated murine models for several autoimmune diseases with mAb against 
MHA II. This treatment was effective in experimental autoimmune encephalitis 
(50) and experimentally induced myasthenia gravis (51). It also increased survival 
in B/W mice, even though it did not reduce autoantibody production (52).  In 
mice, MHA II are expressed on macrophages, B cells, and activated T  cells (53), 
but it is not known whether successful treatment with mAb against MHA II is 
associated with depletion of these cell types. In humans, MHA II are expressed 
not only on certain lymphoid cells, but also on blood vessel endothelial cells (54). 
This may account for the severe toxicity of mAb against MHA II in monkeys 
(55), which may complicate the use of anti-MHA II in humans. Unlike MHA II, 
L3T4 appears to be restricted in its expression to a distinct subpopulation of T 
lymphocytes  and T  lymphocyte precursors (24). Therefore, anti-L3T4 mAb may 
provide an alternative to  the use of anti-MHA  II  mAb that  would be  more 
selective in  its effect on the immune system. The human homologue for the WOFSY  AND  SEAMAN  387 
L3T4 antigen has been identified (23), and mAb against this antigen have already 
been used to prolong renal allograft survival in nonhuman primates (19). 
Treatment of B/W mice with anti-L3T4 had profound effects on the immune 
system that raise questions about the immune competence of treated mice. The 
reduction in L3T4  ÷ T  cells creates an imbalance between T  cell subpopulations 
that resembles the distribution of T  cell subsets in acquired immunodeficiency 
syndrome (AIDS)  in  people  (56).  The  beneficial  reduction  in  antibodies  to 
double-stranded DNA and antibodies to rat Ig may reflect a  more generalized 
impairment of humoral immunity. Our studies do not establish the significance 
of these alterations in cellular and humoral immunity, but they do provide some 
preliminary insight. Despite a  10-fold reduction in autoantibody concentration, 
treatment  with  anti-L3T4  did  not  significantly depress  Ig  levels.  Moreover, 
treated mice did not develop infectious complications, even though they were 
housed  without  special  precautions  in  our  main  animal  colony.  Studies  are 
currently  in  progress  in  our  laboratory  to  determine  the  precise  effects of 
treatment with anti-L3T4 on immune competence in normal and autoimmune 
mice. 
The immunologic abnormalities in B/W mice closely parallel the immunologic 
abnormalities underlying SLE  in  humans.  T  lymphocytopenia, impaired sup- 
pressor T cell function, reduced lymphokine production, and B cell hyperactivity 
all occur in humans with SLE as well as in B/W mice, but the significance of 
these abnormalities remains controversial (32, 57-60). There is no fixed abnor- 
mality in the relative proportion of circulating T  cell subsets in either B/W mice 
or humans with SLE (61), but our results make it clear that this does not exclude 
the  possibility  that  T  cells  regulate  autoimmunity  in  SLE.  The  similarities 
between SLE in  humans and SLE in  B/W  mice suggest that they may share 
common pathogenetic mechanisms. Our findings in B/W mice therefore support 
the hypothesis that autoimmunity in people with SLE is regulated by T  cells. 
This hypothesis is consistent with recent studies indicating that total lymphoid 
irradiation  (TLI)  improves lupus  nephritis  in  humans (62-64).  Although the 
effect of TLI on lymphocyte subsets in SLE has not yet been determined, TLI 
causes prolonged depletion and impaired function of Leu-3/T4  + cells in people 
with rheumatoid arthritis (65-67). These observations add weight to the possi- 
bility that treatment with mAb against Leu-3/T4 would favorably influence the 
course of autoimmune disease in people with SLE.  However, we believe that 
such treatment would be premature until the effects of anti-L3T4 on normal 
immune function have been thoroughly investigated. 
Summary 
Autoimmune NZB/NZW mice were treated with weekly injections of mono- 
clonal antibody (mAb) to L3T4, an antigen expressed on a distinct subpopulation 
of T  cells that respond to class II major histocompatibility antigens. Treatment 
with anti-L3T4 depleted circulating target cells, reduced autoantibody produc- 
tion, retarded renal disease, and prolonged life relative to control mice treated 
either with saline or with purified nonimmune rat IgG. These findings establish 
that autoimmune disease in NZB/NZW mice is regulated by T  cells. In contrast 
to mice treated with nonimmune rat IgG, mice treated with rat anti-LST4 mAb 388  SUCCESSFUL  TREATMENT OF  NZB/NZW Fi  MICE WITH ANTI-L3T4 
developed little or no antibody to rat Ig.  Thus, the benefits of treatment with 
anti-L3T4  were  achieved  while  minimizing  the  risks  associated  with  a  host 
immune response to therapy. This study raises the possibility that treatment with 
mAb against Leu-3/T4, the human homologue for L3T4, might be effective in 
the treatment of certain autoimmune diseases in people. 
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